A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT03958864
- Locations
- 🇺🇸
Paraxel International, Glendale, California, United States
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Conditions
- Primary MyelofibrosisMyelofibrosisPost-Polycythemia Vera
- Interventions
- Drug: Best Available Therapy (BAT)
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 202
- Registration Number
- NCT03952039
- Locations
- 🇦🇹
Local Institution - 153, Wels, Austria
🇦🇹Local Institution - 155, Linz, Austria
🇦🇹Local Institution - 151, Salzburg, Austria
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 438
- Registration Number
- NCT03930953
- Locations
- 🇺🇸
Local Institution - 114, Los Angeles, California, United States
🇩🇰Rigshospitalet University Hospital, Copenhagen, Denmark
🇩🇰Local Institution - 603, Vejle, Denmark
To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 195
- Registration Number
- NCT03915769
- Locations
- 🇯🇵
Local Institution - 122, Chikushino, Japan
🇯🇵Local Institution - 119, Ogaki, Japan
🇯🇵Local Institution - 139, Abiko, Japan
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT03906526
- Locations
- 🇺🇸
Local Institution - 103, Sioux Falls, South Dakota, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT03900715
- Locations
- 🇯🇵
Local Institution - 344, Nagasaki-shi, Nagasaki, Japan
🇯🇵Local Institution - 331, Kamogawa, Japan
🇯🇵Local Institution - 348, Kitakyushu, Japan
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT03850067
- Locations
- 🇪🇸
Local Institution - 406, Majadahonda, Madrid, Spain
🇫🇷Local Institution - 102, Marseille Cedex 5, France
🇪🇸Local Institution - 402, Barcelona, Spain
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03824678
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT03803644
- Locations
- 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 230
- Registration Number
- NCT03783403
- Locations
- 🇺🇸
Local Institution - 107, Pittsburgh, Pennsylvania, United States
🇺🇸Local Institution - 108, Houston, Texas, United States
🇺🇸Local Institution - 103, San Antonio, Texas, United States